Literature DB >> 28932552

Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis.

Nikoletta R Czobor1, György Roth1, Zsolt Prodán2, Daniel J Lex1, Erzsébet Sápi3, László Ablonczy3, Mihály Gergely3, Edgar A Székely3, János Gál4, Andrea Székely3,4.   

Abstract

BACKGROUND: The occurrence of postoperative chylothorax in children with congenital heart disease is a rare and serious complication in cardiac intensive care units (ICUs). The aim of our study was to identify the perioperative characteristics, treatment options, resource utilization and long term complications of patients having chylothorax after a pediatric cardiac surgery.
METHODS: Patients were retrospectively assessed for the presence of chylothorax between January 2002 and December 2012 in a tertiary national cardiac center. Occurrence, treatment options and long term outcomes were analyzed. Chylothorax patients less than 2 years of age were analyzed using propensity-matched statistical analysis in regard to postoperative complications after discharge.
RESULTS: During the 10-year period, 48 patients had chylothorax after pediatric cardiac surgery. The highest incidence was observed on the second postoperative day (7 patients, 14.6%). Seven patients (14.6% of the chylothorax population) died. During the follow up period, 5 patients had additional thromboembolic complications (2 had confirmed thrombophilia). Eleven patients had a genetic abnormality (3 had Down's syndrome, 3 had Di-Giorge's syndrome, 1 had an IgA deficiency and 4 had other disorders). During the reoperations (49 cases), no chylothorax occurred. After propensity matching, the occurrence of pulmonary failure (P=0.001) was significantly higher in the chylothorax group, and they required prolonged mechanical ventilation (P=0.002) and longer hospitalization times (P=0.01). After discharge, mortality and neurologic and thromboembolic events did not differ in the matched groups.
CONCLUSIONS: Chylothorax is an uncommon complication after pediatric cardiac surgery and is associated with higher resource utilization. Chylothorax did not reoccur during reoperations and was not associated with higher mortality or long-term complications in a propensity matched analysis.

Entities:  

Keywords:  Chylothorax; congenital heart disease; long-term outcome; median-chain triglyceride-diet; octreotide therapy; pediatric cardiac surgery

Year:  2017        PMID: 28932552      PMCID: PMC5594187          DOI: 10.21037/jtd.2017.07.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  37 in total

Review 1.  Management of postoperative chylothorax.

Authors:  M Chalret du Rieu; J Baulieux; A Rode; J-Y Mabrut
Journal:  J Visc Surg       Date:  2011-10-26       Impact factor: 2.043

2.  Octreotide in the management of postoperative chylothorax.

Authors:  L Rosti; F De Battisti; G Butera; S Cirri; M Chessa; A Delogu; M Drago; A Giamberti; G Pomè; M Carminati; A Frigiola
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

3.  Treatment of a persistent postoperative chylothorax with somatostatin.

Authors:  P C Rimensberger; B Müller-Schenker; A Kalangos; M Beghetti
Journal:  Ann Thorac Surg       Date:  1998-07       Impact factor: 4.330

4.  Thoracoscopic ligation of the thoracic duct.

Authors:  R B Kent; T W Pinson
Journal:  Surg Endosc       Date:  1993 Jan-Feb       Impact factor: 4.584

Review 5.  Early thoracic duct ligation for postoperative chylothorax.

Authors:  E M Sieczka; J C Harvey
Journal:  J Surg Oncol       Date:  1996-01       Impact factor: 3.454

6.  Octreotide efficacy in the treatment of chylothoraces following cardiac surgery in infants and children.

Authors:  Maple T Landvoigt; Charles J Mullett
Journal:  Pediatr Crit Care Med       Date:  2006-05       Impact factor: 3.624

7.  Surgical treatment of chylothorax caused by cardiothoracic surgery in children.

Authors:  Chin-Su Liu; Hsin-Lin Tsai; Tai-Wai Chin; Chou-Fu Wei
Journal:  J Chin Med Assoc       Date:  2005-05       Impact factor: 2.743

8.  Management of chylothorax.

Authors:  N L Browse; D R Allen; N M Wilson
Journal:  Br J Surg       Date:  1997-12       Impact factor: 6.939

Review 9.  Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review.

Authors:  Charles C Roehr; Andreas Jung; Hans Proquitté; Oliver Blankenstein; Hannes Hammer; Kokila Lakhoo; Roland R Wauer
Journal:  Intensive Care Med       Date:  2006-03-11       Impact factor: 17.440

10.  Management of pediatric postoperative chylothorax.

Authors:  S J Bond; P C Guzzetta; M L Snyder; J G Randolph
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

View more
  3 in total

Review 1.  Lymphatic dysfunction in critical illness.

Authors:  Edmund Burke; Sanjeev A Datar
Journal:  Curr Opin Pediatr       Date:  2018-06       Impact factor: 2.856

Review 2.  Octreotide for Acquired Chylothorax in Pediatric Patients Post-Cardiothoracic Surgery for Congenital Heart Disease: A Systematic Review.

Authors:  A C Jenkinson; J McGuinness; T Prendiville
Journal:  Pediatr Cardiol       Date:  2022-10-18       Impact factor: 1.838

3.  Causes and manifestations of chylothorax in children in China: Experience from a children's medical center, 2007-2017.

Authors:  Yan Guo; Jiehua Chen; Baoping Xu; Yuejie Zheng; Kunling Shen
Journal:  Pediatr Investig       Date:  2018-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.